Barely Significant
← all excerpts

Lupus clinical trials and the promise of future therapies.

Rheumatol Immunol Res · 2023 · PMC10538598 · PMID 37781678

Europe PMCDOI
1
hedged sentence
0.1830
closest p · 3.7× alpha
0.1830
boldest claim

The sentences

did not reach statistical significanceP = 0.183not close (p > 0.1)
The primary endpoint, proportion of patients reaching Week 32 without LOI, did not reach statistical significance: 21/50 (42.0%) obexelimab-treated vs . 12/42 (28.6%) placebo-treated patients ( P = 0.183).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.